MCID: HPT014
MIFTS: 46

Hepatorenal Syndrome malady

Categories: Rare diseases, Gastrointestinal diseases, Nephrological diseases, Liver diseases

Aliases & Classifications for Hepatorenal Syndrome

Aliases & Descriptions for Hepatorenal Syndrome:

Name: Hepatorenal Syndrome 12 50 52 42 14 69
Hepato-Renal Syndrome 50

Classifications:



External Ids:

Disease Ontology 12 DOID:11823
ICD10 33 K76.7
ICD9CM 35 572.4
MeSH 42 D006530
NCIt 47 C113400
SNOMED-CT 64 51292008
UMLS 69 C0019212

Summaries for Hepatorenal Syndrome

NIH Rare Diseases : 50 hepatorenal syndrome is a form of impaired kidney function that occurs in individuals with advanced chronic liver disease. as many as 40% of individuals with cirrhosis and ascites will develop hepatorenal syndrome. symptoms may include fatigue, abdominal pain, and a general feeling of ill health (malaise). there are two distinct types of hepatorenal syndrome. type i progresses quickly (within days), leading to kidney failure. individuals with type i typically have dramatically reduced urine output, edema, and jaundice, and often suffer from hepatic encephalopathy. type ii progresses more slowly, over weeks or months, and the symptoms are less severe. the cause of hepatorenal syndrome is unknown. a contributing factor seems to be a narrowing of the blood vessels that connect into the kidneys. this causes a decrease in blood flow to the kidneys, impairing their function. in some cases, triggers or precipitating factors (infections, blood loss from the gastrointestinal tract, low blood pressure) are involved. treatment is aimed at helping the liver work better and maintaining kidney function. in many cases, a liver transplant is needed. in some cases, individuals also need a kidney transplant.  last updated: 7/13/2016

MalaCards based summary : Hepatorenal Syndrome, also known as hepato-renal syndrome, is related to zellweger syndrome and obstructive jaundice. An important gene associated with Hepatorenal Syndrome is ALB (Albumin), and among its related pathways/superpathways are FOXA2 and FOXA3 transcription factor networks and A-beta Pathways: Plaque Formation and APP Metabolism. The drugs Adefovir Dipivoxil and Telbivudine have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and neutrophil, and related phenotypes are homeostasis/metabolism and cardiovascular system

Wikipedia : 71 Hepatorenal syndrome (often abbreviated HRS) is a life-threatening medical condition that consists of... more...

Related Diseases for Hepatorenal Syndrome

Diseases related to Hepatorenal Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 155)
id Related Disease Score Top Affiliating Genes
1 zellweger syndrome 30.0 ALB EDN1
2 obstructive jaundice 29.8 ALB EDN1 F2
3 peroxisome biogenesis disorder 1a 11.0
4 joubert syndrome with oculorenal anomalies 11.0
5 transsexualism 10.3 ALB REN
6 antiphospholipid syndrome 10.3 ALB REN
7 hepatitis 10.3
8 nondystrophic myotonia 10.3 ALB F2
9 uterine inflammatory disease 10.3 EDN1 REN
10 freiberg's disease 10.3 ALB F2
11 hepatic infarction 10.3 EDN1 REN
12 adenocarcinoma 10.3 EDN1 REN
13 pharynx carcinoma in situ 10.2 ALB F2
14 influenza 10.2 F2 REN
15 female infertility of uterine origin 10.2 ALB F2
16 bile duct cystadenocarcinoma 10.2 ALB F2
17 endometrial mixed adenocarcinoma 10.2 F2 REN
18 duane retraction syndrome 10.2 ALB F2
19 chronic inflammatory demyelinating polyneuritis 10.2 ALB F2
20 citrulline transport defect 10.2 EDN1 F2
21 angelucci's syndrome 10.2 ALB F2
22 autonomic neuropathy 10.2 F2 REN
23 hypotrichosis simplex 10.2 ACE REN
24 kohler's disease 10.2 ALB F2
25 ovarian papillary cystadenoma 10.2 ALB F2
26 hyperinsulinemic hypoglycemia, familial, 3 10.2 ACE REN
27 carbohydrate metabolic disorder 10.2 ACE REN
28 hemorrhoid 10.2 EDN1 REN
29 hypothyroidism, congenital nongoitrous, 5 10.2 ACE REN
30 listeriosis 10.2 ACE REN
31 dientamoebiasis 10.2 ACE REN
32 spondyloarthropathy 2 10.2 ACE ALB
33 shaken baby syndrome 10.2 NPPA REN
34 infiltrating ureter transitional cell carcinoma 10.2 ALB F2
35 familial progressive hyperpigmentation 10.2 ACE F2
36 eagle syndrome 10.2 ALB F2
37 achromatopsia 10.2 NPPA REN
38 cascade stomach 10.2 ACE REN
39 blackwater fever 10.2 EDN1 NPPA
40 atrophic vulva 10.2 ALB F2
41 hyperuricemic nephropathy, familial juvenile 2 10.2 ACE REN
42 chylocele of tunica vaginalis 10.2 ACE REN
43 lymphocytic colitis 10.2 ACE F2
44 retinal arterial macroaneurysm with supravalvular pulmonic stenosis 10.2 ALB F2
45 acute monocytic leukemia 10.2 ALB F2
46 agammaglobulinemia 6 10.2 ACE ALB
47 bullous skin disease 10.2 ACE F2
48 aplasia cutis congenita recessive 10.1 ACE EDN1
49 flat umbilicus familial 10.1 ACE REN
50 bacterial conjunctivitis 10.1 ALB IL18

Comorbidity relations with Hepatorenal Syndrome via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alcoholic Liver Cirrhosis
Chronic Kidney Failure Deficiency Anemia
Heart Disease Hepatic Encephalopathy
Portal Hypertension

Graphical network of the top 20 diseases related to Hepatorenal Syndrome:



Diseases related to Hepatorenal Syndrome

Symptoms & Phenotypes for Hepatorenal Syndrome

MGI Mouse Phenotypes related to Hepatorenal Syndrome:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.91 IL18 NPPA REN ACE ALB AQP2
2 cardiovascular system MP:0005385 9.87 ACE CST3 EDN1 F2 IL18 NPPA
3 mortality/aging MP:0010768 9.76 REN ACE ALB AQP2 CST3 EDN1
4 muscle MP:0005369 9.43 ALB CST3 EDN1 IL18 NPPA REN
5 renal/urinary system MP:0005367 9.1 ACE ALB AQP2 EDN1 NPPA REN

Drugs & Therapeutics for Hepatorenal Syndrome

Drugs for Hepatorenal Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 157)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adefovir Dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
2
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
3
Terlipressin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 14636-12-5 72081
4
Norfloxacin Approved Phase 4 70458-96-7 4539
5
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
6
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
7
Tranexamic Acid Approved Phase 4 1197-18-8 5526
8 Adefovir Phase 4
9 Anti-Infective Agents Phase 4,Phase 3,Phase 2
10 Anti-Retroviral Agents Phase 4
11 Antiviral Agents Phase 4,Phase 2
12 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1
13 Nucleic Acid Synthesis Inhibitors Phase 4
14 Reverse Transcriptase Inhibitors Phase 4
15 Antihypertensive Agents Phase 4,Phase 2,Phase 3,Phase 1
16 Coagulants Phase 4,Phase 2,Phase 3,Phase 1
17 Hemostatics Phase 4,Phase 2,Phase 3,Phase 1
18 Lypressin Phase 4,Phase 2,Phase 3,Phase 1
19 Natriuretic Agents Phase 4,Phase 2,Phase 3,Phase 1
20 Vasoconstrictor Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
21 Adrenergic Agents Phase 4,Phase 3,Phase 2,Early Phase 1
22 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Early Phase 1
23 Vasodilator Agents Phase 4,Phase 3
24 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
25 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
26 Cytochrome P-450 Enzyme Inhibitors Phase 4
27 Topoisomerase Inhibitors Phase 4
28 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
29 Adrenergic alpha-1 Receptor Antagonists Phase 4
30 Adrenergic alpha-Antagonists Phase 4
31 Adrenergic Antagonists Phase 4,Phase 3
32 Adrenergic beta-Antagonists Phase 4,Phase 3
33 Anticoagulants Phase 4
34 Antifibrinolytic Agents Phase 4
35 Blood Substitutes Phase 4
36 Dextrans Phase 4
37 Plasma Substitutes Phase 4
38
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
39
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
40
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
41
Midodrine Approved Phase 2, Phase 3 133163-28-7, 42794-76-3 4195
42
Octreotide Approved, Investigational Phase 2, Phase 3 83150-76-9 383414 6400441
43
Norepinephrine Approved Phase 3,Phase 2,Early Phase 1 51-41-2 439260
44
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
45
Dopamine Approved Phase 2, Phase 3 51-61-6, 62-31-7 681
46
Basiliximab Approved, Investigational Phase 3 152923-56-3, 179045-86-4
47
Everolimus Approved Phase 3 159351-69-6 6442177
48
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
49
Mycophenolate mofetil Approved, Investigational Phase 3 128794-94-5 5281078
50
Mycophenolic acid Approved Phase 3 24280-93-1 446541

Interventional clinical trials:

(show top 50) (show all 76)
id Name Status NCT ID Phase
1 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4
2 Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis Completed NCT00359853 Phase 4
3 Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention Completed NCT01542801 Phase 4
4 The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure Recruiting NCT02489864 Phase 4
5 Early Precise Diagnosis and Intervention of CPT Based on a Noninvasive 3D-vHPS Recruiting NCT02925975 Phase 4
6 Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response Active, not recruiting NCT01530711 Phase 4
7 Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding Not yet recruiting NCT03023189 Phase 4
8 Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin Suspended NCT00287664 Phase 4
9 The INFECIR-2 Albumin Prevention Study Terminated NCT02034279 Phase 4
10 Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis Terminated NCT00570960 Phase 4
11 Terlipressin Given As I.V. Boluses Versus Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome Unknown status NCT00742690 Phase 2, Phase 3
12 Short-term Survival in Patients With Severe Alcoholic Hepatitis Treated With Steroid Versus Pentoxifylline Unknown status NCT01455337 Phase 3
13 Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1 Completed NCT00089570 Phase 3
14 Noradrenalin vs Terlipressin in Hepatorenal Syndrome Completed NCT00370253 Phase 3
15 A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin Completed NCT01143246 Phase 3
16 TYPE 2 HEPATORENAL SYNDROME Completed NCT01637454 Phase 3
17 The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction Completed NCT00240045 Phase 2, Phase 3
18 Terlipressin in Septic Shock in Cirrhosis Completed NCT00628160 Phase 2, Phase 3
19 Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection. Completed NCT00502086 Phase 3
20 CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment Completed NCT00604357 Phase 3
21 Double-blind Randomized Controlled Trial in Severe Alcoholic Hepatitis Completed NCT01214226 Phase 3
22 A Study To Confirm Efficacy and Safety of Terlipressin in HRS Type 1 Recruiting NCT02770716 Phase 3
23 Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction Recruiting NCT01453218 Phase 3
24 Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study Recruiting NCT02451033 Phase 2, Phase 3
25 Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis Treated With Prednisolone Recruiting NCT02281929 Phase 3
26 To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites Recruiting NCT02649335 Phase 3
27 Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites Active, not recruiting NCT02173288 Phase 2, Phase 3
28 Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome Terminated NCT00742339 Phase 2, Phase 3
29 Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE Withdrawn NCT00787436 Phase 3
30 Low-dose Albumin Solution in SBP: a Randomized Double-blind Pilot Study Unknown status NCT00852800 Phase 2
31 Adrenal Insufficiency in Cirrhotics With Ascites. Effects of Hydrocortisone on Renal and Haemodynamic Function Unknown status NCT00657306 Phase 2
32 Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients Completed NCT01436500 Phase 2
33 A Study of Terlipressin in Patients With Hepatorenal Syndrome Type 1 Completed NCT01373606 Phase 1, Phase 2
34 Single Pass Albumin Dialysis in Patients With Cirrhosis Completed NCT00764049 Phase 1, Phase 2
35 A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis Completed NCT00562783 Phase 2
36 The Efficacy and Safety of Entecavir Treatment of Patients With Acute on Chronic Hepatitis B Liver Failure Completed NCT01254994 Phase 2
37 Midodrine and Albumin for Cirrhotic Patients With Functional Renal Impairment Completed NCT01133795 Phase 2
38 Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure Recruiting NCT01587222 Phase 2
39 Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH) Recruiting NCT02854631 Phase 2
40 UC-MSC Infusion for HBV-Related Acute-on-Chronic Liver Failure Not yet recruiting NCT02812121 Phase 2
41 Efficacy and Safety of Dexamethasone Prevention for Patients of Ovarian Hyperstimulation Syndrome Not yet recruiting NCT02846493 Phase 2
42 A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome Terminated NCT01906307 Phase 1
43 Evaluation of Renal Blood Flow Using Contrast Enhanced Ultrasound for Differential Diagnosis of Acute Kidney Injury in Cirrhotic Patients: A Pilot Study Unknown status NCT02147470
44 Prognosis Scoring System for Acute-on-Chronic Liver Failure Unknown status NCT01961440
45 Intensive Education on Lipid Management Unknown status NCT01925079
46 Treatment of Type-1 Hepatorenal Syndrome Associated With Sepsis Completed NCT01932151
47 Plasma and Hemodynamic Markers During Hepatectomy Completed NCT01700231
48 To Compare the Response Rate of Noradrenaline vs. Terlipressin in Hepatorenal Syndrome in Patients With Acute on Chronic Liver Failure Completed NCT02573727
49 Evaluation of Probiotics in the Treatment of Portal Hypertension Completed NCT00831337
50 A Trial to Study the Influence of Growth Factors on Bone Marrow and Hepatic Regeneration in Patients With Decompensated Cirrhosis. Completed NCT01902511

Search NIH Clinical Center for Hepatorenal Syndrome

Cochrane evidence based reviews: hepatorenal syndrome

Genetic Tests for Hepatorenal Syndrome

Anatomical Context for Hepatorenal Syndrome

MalaCards organs/tissues related to Hepatorenal Syndrome:

39
Liver, Kidney, Neutrophil, Heart, Bone, Skin, Breast

Publications for Hepatorenal Syndrome

Articles related to Hepatorenal Syndrome:

(show top 50) (show all 594)
id Title Authors Year
1
Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1. ( 28052382 )
2017
2
Cirrhotic Cardiomyopathy: Another Case of a Successful Approach to Treatment of Hepatorenal Syndrome. ( 27843430 )
2016
3
Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: Implications for its safety profile. ( 27586252 )
2016
4
Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation. ( 26649801 )
2016
5
Is MELD score failing patients with liver disease and hepatorenal syndrome? ( 27721921 )
2016
6
Outcomes of liver transplantation in patients with hepatorenal syndrome. ( 27648152 )
2016
7
A Hepatorenal syndrome: Current concepts related to diagnosis and management. ( 27236146 )
2016
8
Serum and urinary biomarkers that predict hepatorenal syndrome in patients with advanced cirrhosis. ( 27876501 )
2016
9
Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis. ( 27655104 )
2016
10
TERLIPRESSIN VERSUS NORADRENALINE FOR HEPATORENAL SYNDROME. Economic evaluation under the perspective of the Brazilian Public Health System. ( 27305421 )
2016
11
Is there any potential or additive effect of anemia on hepatorenal syndrome? ( 27210785 )
2016
12
Fractional excretion of sodium in hepatorenal syndrome: Clinical and pathological correlation. ( 28008340 )
2016
13
Acute kidney injury in cirrhosis besides hepatorenal syndrome. ( 27727684 )
2016
14
The trigger matters - outcome of hepatorenal syndrome versus specifically-triggered AKI in cirrhotic patients with ascites. ( 27169985 )
2016
15
Hepatorenal syndrome in cirrhosis: diagnostic, pathophysiological, and therapeutic aspects. ( 27248461 )
2016
16
Hepatorenal syndrome:Response to terlipressin and albumin and its determinants. ( 27182222 )
2016
17
Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. ( 26896734 )
2016
18
Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. ( 26659927 )
2016
19
Therapeutic alternatives for the treatment of type 1 hepatorenal syndrome: A Delphi technique-based consensus. ( 27660674 )
2016
20
Point-of-Care Echocardiography Improves Assessment of Volume Status in Cirrhosis and Hepatorenal Syndrome. ( 27140719 )
2016
21
Noradrenaline is as Effective as Terlipressin in Hepatorenal Syndrome Type 1: A Prospective, Randomized Trial. ( 27762512 )
2016
22
The clinical management of abdominal ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: a review of current guidelines and recommendations. ( 26671516 )
2016
23
Terlipressin administration for type 1 hepatorenal syndrome. More answers than open questions. ( 27186863 )
2016
24
Association of eNOS Gene Polymorphisms G894T and T-786C with Risk of Hepatorenal Syndrome. ( 27594880 )
2016
25
Hepatorenal Syndrome: Diagnosis and Treatment - newsreel. ( 27658161 )
2016
26
Population Based Trends in the Incidence of Hospital Admission for the Diagnosis of Hepatorenal Syndrome: 1998-2011. ( 27144022 )
2016
27
Clinical Scenarios in Acute Kidney Injury: Hepatorenal Syndrome. ( 27169751 )
2016
28
Progressive liver failure post acute hepatitis A, over a three-month period, resulting in hepatorenal syndrome and death. ( 27247182 )
2016
29
Hepatorenal syndrome in hospitalized patients with chronic liver disease: results from the Nationwide Inpatient Sample 2002-2012. ( 26755811 )
2016
30
Red signs and not severity of cirrhosis should determine non-selective I^-blocker treatment in Child-Pugh C cirrhosis with small varices: increased risk of hepatorenal syndrome and death beyond 6a88months of propranolol use. ( 26935875 )
2016
31
Influence of hepatorenal syndrome on outcome of living donor liver transplantation: A single-center experience in 357 patients. ( 27323334 )
2016
32
Management of Hepatorenal Syndrome in the Era of Acute-on-Chronic Liver Failure: Telipressin and Beyond. ( 27133393 )
2016
33
Hepatorenal syndrome. ( 27372112 )
2016
34
Evidence-Based Therapeutic Options for Hepatorenal Syndrome. ( 26922867 )
2016
35
Recovery of Native Renal Function in Patients with Hepatorenal Syndrome Following Combined Liver and Kidney Transplant with Mercaptoacetyltriglycine-3 Renogram: Developing a Methodology. ( 26912978 )
2016
36
Hepatorenal syndrome: outcome of response to therapy and predictors of survival. ( 25983746 )
2015
37
The Treatment of Hepatorenal Syndrome. ( 26159272 )
2015
38
Outpatients use of terlipressin for hepatorenal syndrome: Not for all, with caution and a wise liver transplant allocation policy. ( 26524375 )
2015
39
Renal impairment in cirrhosis unrelated to hepatorenal syndrome. ( 25874649 )
2015
40
Hepatorenal syndrome: aetiology, diagnosis, and treatment. ( 25649410 )
2015
41
Renal outcomes after liver transplantation in fulminant hepatitis a with acute kidney injury: comparison with hepatorenal syndrome. ( 25891716 )
2015
42
Noradrenaline or terlipressin for hepatorenal syndrome? ( 26334297 )
2015
43
Dopamine and Furosemide for the Treatment of Hepatorenal Syndrome: A Reappraisal or Just Smoke and Mirrors? ( 26900267 )
2015
44
Pretransplant Type 2 Hepatorenal Syndrome Is Associated With Persistently Impaired Renal Function After Liver Transplantation. ( 25643142 )
2015
45
Terlipressin Versus Noradrenaline In The Treatment Of Hepatorenal Syndrome - Systematic Review With Meta-Analysis And Full Economic Evaluation. ( 26534638 )
2015
46
Is type 2 hepatorenal syndrome still a potential indication for treatment with terlipressin and albumin? ( 26369385 )
2015
47
Randomized Controlled Trial Comparing the Efficacy of Terlipressin and Albumin with a Combination of Concurrent Dopamine, Furosemide, and Albumin in Hepatorenal Syndrome. ( 26900268 )
2015
48
Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor plus albumin. ( 26051980 )
2015
49
Predictors of hepatorenal syndrome in alcoholic liver cirrhosis. ( 25820623 )
2015
50
Magnetic resonance elastography in the detection of hepatorenal syndrome in patients with cirrhosis and ascites. ( 25903705 )
2015

Variations for Hepatorenal Syndrome

Expression for Hepatorenal Syndrome

Search GEO for disease gene expression data for Hepatorenal Syndrome.

Pathways for Hepatorenal Syndrome

Pathways related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.8 ALB F2
2 10.37 ACE CST3
3 10.02 F2 IL18

GO Terms for Hepatorenal Syndrome

Cellular components related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 ACE ALB CST3 EDN1 F2 IL18
2 endoplasmic reticulum lumen GO:0005788 9.33 ALB CST3 F2
3 extracellular space GO:0005615 9.23 ACE ALB CST3 EDN1 F2 IL18

Biological processes related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.61 CST3 EDN1 NPPA
2 negative regulation of proteolysis GO:0045861 9.48 CST3 F2
3 regulation of vasoconstriction GO:0019229 9.46 ACE EDN1
4 positive regulation of heart rate GO:0010460 9.4 EDN1 NPPA
5 regulation of blood vessel size GO:0050880 9.37 EDN1 NPPA
6 response to muscle stretch GO:0035994 9.32 EDN1 NPPA
7 beta-amyloid metabolic process GO:0050435 9.26 ACE REN
8 cellular protein metabolic process GO:0044267 9.26 ALB CST3 F2 NPPA
9 angiotensin maturation GO:0002003 9.16 ACE REN
10 regulation of blood pressure GO:0008217 8.92 ACE EDN1 NPPA REN

Molecular functions related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 receptor binding GO:0005102 8.92 EDN1 F2 NPPA REN

Sources for Hepatorenal Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....